-
Je něco špatně v tomto záznamu ?
Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes
D. Karasek, J. Spurna, V. Kubickova, O. Krystynik, L. Cibickova, J. Schovanek, D. Goldmannova
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- biologické markery krev MeSH
- diabetes mellitus 2. typu krev diagnóza MeSH
- dospělí MeSH
- inhibitor aktivátoru plazminogenu 1 krev MeSH
- inzulinová rezistence fyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- neurotrofní faktory krev MeSH
- oční proteiny krev MeSH
- průřezové studie MeSH
- senioři MeSH
- serpiny krev MeSH
- von Willebrandův faktor metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction. Fifty T2D individuals and forty healthy controls were included. PEDF, PAI-1, vWF, anthropological parameters, lipids, and markers of insulin resistance were investigated in all subjects. Compared to controls only MetS+ diabetics had higher PEDF levels [14.2 (10.2-16.0) mg/l vs. 11.1 (8.6-14.4) mg/l; p<0.05]. PEDF significantly correlated: positively with body mass index (rho=0.25), smoking (rho=0.21), C-reactive protein (rho=0.22), triglycerides (rho=0.38), non-HDL-cholesterol (rho=0.39), apolipoprotein B (rho=0.38), fasting glucose (rho=0.22), glycated hemoglobin (rho=0.24), C-peptide (rho=0.28), insulin (rho=0.26); and negatively with HDL-cholesterol (rho=-0.42) and apolipoprotein A1 (rho=-0.27). Independent association of PEDF with vWF in T2DMetS- subjects was found. Significantly elevated PEDF in T2DMet+ patients and its association with adverse metabolic profile confirmed PEDF as a marker of insulin resistance. Negative independent association of PEDF with vWF in T2DMetS- patients may reveal its angio-protective role.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19043776
- 003
- CZ-PrNML
- 005
- 20200122082407.0
- 007
- ta
- 008
- 200107s2019 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934013 $2 doi
- 035 __
- $a (PubMed)30904010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Karásek, David $7 stk2007415300 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 245 10
- $a Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes / $c D. Karasek, J. Spurna, V. Kubickova, O. Krystynik, L. Cibickova, J. Schovanek, D. Goldmannova
- 504 __
- $a Literatura
- 520 9_
- $a To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction. Fifty T2D individuals and forty healthy controls were included. PEDF, PAI-1, vWF, anthropological parameters, lipids, and markers of insulin resistance were investigated in all subjects. Compared to controls only MetS+ diabetics had higher PEDF levels [14.2 (10.2-16.0) mg/l vs. 11.1 (8.6-14.4) mg/l; p<0.05]. PEDF significantly correlated: positively with body mass index (rho=0.25), smoking (rho=0.21), C-reactive protein (rho=0.22), triglycerides (rho=0.38), non-HDL-cholesterol (rho=0.39), apolipoprotein B (rho=0.38), fasting glucose (rho=0.22), glycated hemoglobin (rho=0.24), C-peptide (rho=0.28), insulin (rho=0.26); and negatively with HDL-cholesterol (rho=-0.42) and apolipoprotein A1 (rho=-0.27). Independent association of PEDF with vWF in T2DMetS- subjects was found. Significantly elevated PEDF in T2DMet+ patients and its association with adverse metabolic profile confirmed PEDF as a marker of insulin resistance. Negative independent association of PEDF with vWF in T2DMetS- patients may reveal its angio-protective role.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a diabetes mellitus 2. typu $x krev $x diagnóza $7 D003924
- 650 _2
- $a oční proteiny $x krev $7 D005136
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulinová rezistence $x fyziologie $7 D007333
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neurotrofní faktory $x krev $7 D009414
- 650 _2
- $a inhibitor aktivátoru plazminogenu 1 $x krev $7 D017395
- 650 _2
- $a serpiny $x krev $7 D015843
- 650 _2
- $a von Willebrandův faktor $x metabolismus $7 D014841
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Spurná, Jaromíra $7 xx0227678 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Kubíčková, Veronika $7 xx0225011
- 700 1_
- $a Krystyník, Ondřej, $d 1983- $7 xx0208134 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Cibičková, Ľubica $7 xx0224082 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Schovánek, Jan $7 xx0227659 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Goldmannová, Dominika $7 xx0227682 $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital and Palacky University, Olomouc, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, č. 3 (2019), s. 409-418
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30904010 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20200107 $b ABA008
- 991 __
- $a 20200122082745 $b ABA008
- 999 __
- $a ok $b bmc $g 1485088 $s 1082443
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c 3 $d 409-418 $e 20190322 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20200107